Clinical trial
The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.
NCT02253004 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.
- Lead sponsor
- Herlev Hospital
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2014
- Completion date
- August 31, 2015
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.